Financhill
Buy
55

VSTM Quote, Financials, Valuation and Earnings

Last price:
$8.32
Seasonality move :
4.27%
Day range:
$6.78 - $8.34
52-week range:
$2.10 - $8.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
27.44x
Volume:
5.3M
Avg. volume:
1.7M
1-year change:
-31.77%
Market cap:
$456.6M
Revenue:
$10M
EPS (TTM):
-$3.42

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VSTM
Verastem
$5.5M -$0.62 -39.89% -100% $15.75
KROS
Keros Therapeutics
$2.9M -$1.04 10251.84% -9.73% $32.20
MRK
Merck &
$17.1B $2.46 -1.55% -4.04% $101.91
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.43 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VSTM
Verastem
$8.31 $15.75 $456.6M -- $0.00 0% --
KROS
Keros Therapeutics
$14.57 $32.20 $591.8M -- $0.00 0% 2.63x
MRK
Merck &
$77.58 $101.91 $194.8B 11.29x $0.81 4.07% 3.08x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.16x
OGEN
Oragenics
$0.19 $1.00 $4.1M -- $0.00 0% 1.84x
TOVX
Theriva Biologics
$0.46 $7.00 $3.7M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VSTM
Verastem
50.52% -1.377 40.34% 3.10x
KROS
Keros Therapeutics
-- 1.088 -- 18.79x
MRK
Merck &
41.89% 0.358 16.34% 0.80x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VSTM
Verastem
-- -$44.2M -78.01% -120.71% -71.18% -$38.7M
KROS
Keros Therapeutics
-- $152M 0.78% 0.78% 71.97% $160.6M
MRK
Merck &
$12.1B $5.9B 21.5% 39.02% 40.03% $1.2B
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Verastem vs. Competitors

  • Which has Higher Returns VSTM or KROS?

    Keros Therapeutics has a net margin of -82.56% compared to Verastem's net margin of 70.27%. Verastem's return on equity of -120.71% beat Keros Therapeutics's return on equity of 0.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.96 $80.9M
    KROS
    Keros Therapeutics
    -- $3.62 $728.9M
  • What do Analysts Say About VSTM or KROS?

    Verastem has a consensus price target of $15.75, signalling upside risk potential of 89.53%. On the other hand Keros Therapeutics has an analysts' consensus of $32.20 which suggests that it could grow by 110.71%. Given that Keros Therapeutics has higher upside potential than Verastem, analysts believe Keros Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    KROS
    Keros Therapeutics
    6 5 0
  • Is VSTM or KROS More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Keros Therapeutics has a beta of 1.321, suggesting its more volatile than the S&P 500 by 32.134%.

  • Which is a Better Dividend Stock VSTM or KROS?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Keros Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or KROS?

    Verastem quarterly revenues are $10M, which are smaller than Keros Therapeutics quarterly revenues of $211.2M. Verastem's net income of -$52.1M is lower than Keros Therapeutics's net income of $148.5M. Notably, Verastem's price-to-earnings ratio is -- while Keros Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 2.63x for Keros Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$52.1M
    KROS
    Keros Therapeutics
    2.63x -- $211.2M $148.5M
  • Which has Higher Returns VSTM or MRK?

    Merck & has a net margin of -82.56% compared to Verastem's net margin of 32.71%. Verastem's return on equity of -120.71% beat Merck &'s return on equity of 39.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.96 $80.9M
    MRK
    Merck &
    77.98% $2.01 $83.2B
  • What do Analysts Say About VSTM or MRK?

    Verastem has a consensus price target of $15.75, signalling upside risk potential of 89.53%. On the other hand Merck & has an analysts' consensus of $101.91 which suggests that it could grow by 31.36%. Given that Verastem has higher upside potential than Merck &, analysts believe Verastem is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    MRK
    Merck &
    12 11 0
  • Is VSTM or MRK More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

  • Which is a Better Dividend Stock VSTM or MRK?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.07% to investors and pays a quarterly dividend of $0.81 per share. Verastem pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios VSTM or MRK?

    Verastem quarterly revenues are $10M, which are smaller than Merck & quarterly revenues of $15.5B. Verastem's net income of -$52.1M is lower than Merck &'s net income of $5.1B. Notably, Verastem's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 3.08x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$52.1M
    MRK
    Merck &
    3.08x 11.29x $15.5B $5.1B
  • Which has Higher Returns VSTM or NBY?

    NovaBay Pharmaceuticals has a net margin of -82.56% compared to Verastem's net margin of -49.65%. Verastem's return on equity of -120.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.96 $80.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About VSTM or NBY?

    Verastem has a consensus price target of $15.75, signalling upside risk potential of 89.53%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.2%. Given that Verastem has higher upside potential than NovaBay Pharmaceuticals, analysts believe Verastem is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is VSTM or NBY More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock VSTM or NBY?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or NBY?

    Verastem quarterly revenues are $10M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Verastem's net income of -$52.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Verastem's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$52.1M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns VSTM or OGEN?

    Oragenics has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.96 $80.9M
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About VSTM or OGEN?

    Verastem has a consensus price target of $15.75, signalling upside risk potential of 89.53%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Verastem, analysts believe Oragenics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    OGEN
    Oragenics
    0 1 0
  • Is VSTM or OGEN More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock VSTM or OGEN?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or OGEN?

    Verastem quarterly revenues are $10M, which are larger than Oragenics quarterly revenues of --. Verastem's net income of -$52.1M is lower than Oragenics's net income of -$2.2M. Notably, Verastem's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$52.1M
    OGEN
    Oragenics
    1.84x -- -- -$2.2M
  • Which has Higher Returns VSTM or TOVX?

    Theriva Biologics has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$0.96 $80.9M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About VSTM or TOVX?

    Verastem has a consensus price target of $15.75, signalling upside risk potential of 89.53%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1438.46%. Given that Theriva Biologics has higher upside potential than Verastem, analysts believe Theriva Biologics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is VSTM or TOVX More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock VSTM or TOVX?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or TOVX?

    Verastem quarterly revenues are $10M, which are larger than Theriva Biologics quarterly revenues of --. Verastem's net income of -$52.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, Verastem's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$52.1M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Henry Schein Stock Be in 5 Years?
Where Will Henry Schein Stock Be in 5 Years?

If you’re looking at Henry Schein (NASDAQ: HSIC) and wondering…

Cisco Stock Forecast: Is It Ready to Surprise Us?
Cisco Stock Forecast: Is It Ready to Surprise Us?

Let’s be real Cisco Systems (NASDAQ: CSCO) hasn’t exactly been…

Where Will Gartner Stock Be in 5 Years?
Where Will Gartner Stock Be in 5 Years?

If you’ve ever wondered what it’s like to invest in…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock